JLE

Médecine thérapeutique / Pédiatrie

MENU

Epidemiology and natural history of pediatric-onset patients with inflammatory bowel disease Volume 22, issue 1, Janvier-Février-Mars 2019

Figures


  • Figure 1

  • Figure 2
Authors
1 CHRU de Lille, Maison régionale de la recherche clinique, Service de santé publique, d’épidémiologie, d’économie de la santé et de la prévention, Registre EPIMAD, 6 rue du Professeur Laguesse, 59045 Lille
2 Inserm LIRIC UMR 995, Faculté de Médecine, Lille
3 CHU Amiens, Hôpital Sud, Service de gastroentérologie, Registre EPIMAD
4 CHU Rouen, Hôpital Charles Nicolle, Service de gastroentérologie, Registre EPIMAD
5 CHU Lille, Hôpital Huriez, Service de gastroentérologie, Registre EPIMAD
6 CHU Lille, Hôpital Jeanne de Flandre, Clinique de Pédiatrie, Registre EPIMAD
* Tirés à part

Inflammatory bowel diseases (IBD) begin in children in 10% of cases in population-based studies. Crohn's Disease (CD) is by far the most common (65% CD and 35% ulcerative colitis (UC)). The distribution of IBD by gender is, in childhood, the opposite of that it is in adults, with a predominance of boys in CD and girls in pediatric-onset UC. In France, incidence of pediatric IBD is 4.4/105 inhabitants of the same age and gender including 3.2 in CD, 1.1 in UC and 0.1 in IBDU. A dramatic increase in the incidence of both CD and UC has been published in France, Europe and North America, foreshadowing an explosion in the number of new diagnosis, management and cost in the coming years, making a real burden in Public Health. In children, CD as UC present a more extensive digestive location at diagnosis with more frequent extra-intestinal manifestations and a severe disease course, requiring rapid and aggressive therapeutic management. At the era of biotherapy, future population-based studies are currently available to determine whether these treatments reduce the rate of intestinal resection and improve the quality of life of these young patients.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License